Vertex Pharmaceuticals Announces Phase 3 STRIVE Study of VX-770 Showed Durable Improvements in Lung Function and Other Measures of Disease Among People With a Specific Type of Cystic Fibrosis

Vertex Pharmaceuticals Incorporated VRTX today announced the final results from its pivotal Phase 3 STRIVE study that evaluated VX-770, a medicine in development that targets the defective protein that causes cystic fibrosis. STRIVE was designed to evaluate VX-770 among 161 people 12 years or older with a mutation known as G551D in the CF gene. Approximately 4 percent of people with CF have at least one copy of the G551D mutation. Data from the study showed rapid improvements in lung function that were sustained through 48 weeks among those who received VX-770, compared to those treated with a placebo. Significant improvements in all key secondary endpoints were observed among people who received VX-770 compared to placebo. Adverse events that occurred more frequently among those treated with VX-770 compared to placebo were headache, upper respiratory tract infections, nasal congestion, rash, dizziness and bacteria in the sputum. These data were presented today at the 34th European Cystic Fibrosis Society Conference in Hamburg, Germany.